Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Steven Kafka, Christopher McGuigan

Premium

Foundation Medicine has appointed Steven Kafka to chief business officer, a newly created position. He joins the company from Aileron Therapeutics, where he served as chief operating officer and chief financial officer. Previously, he was vice president of finance for Infinity Pharmaceuticals and senior director of finance at Millennium Pharmaceuticals. He holds a BA from Stanford University and a PhD from Harvard University.


Christopher McGuigan has been appointed to serve on Trovagene's board of directors.

McGuigan has been head of medicinal chemistry at Cardiff University and a professor at the Welsh School of Pharmacy since 1995, and last year he was appointed pro vice chancellor at the school. He also is a member of the editorial board for the Journal of Molecular Pharmaceutics and a former president of the International Society for Antiviral Research.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.